0.000USD0.000盘前交易 08/03, 09:30 (美东)
关键数据
1.930今开
1.940最高
34.17K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.01%换手率
1.930昨收
1.895最低
49.12K成交额
亏损市盈率静
0.84市净率
0.00%股息率 TTM
-11.32%ROA
4.44052周最高
0.56量比
-212.07M净利润
355.33M总股本
-0.6369每股收益TTM
1.93Beta
-25.21%ROE
2.30852周最低
2.33%振幅
-1.00%毛利率
699.31M总市值
-18.74回报/风险
1.81%风险率
操作建议
Evotec SE当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名122/385位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价2.80。中期看,股价处于下降通道。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Evotec SE新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Evotec SE简介
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
公司代码EVO
公司Evotec SE
CEOWojczewski (Christian)
网址https://www.evotec.com/
公司股东
常见问题
Evotec SE(EVO)的当前股价是 1.91。
现在Evotec SE(EVO)的股票是买入、持有还是卖出?
根据分析师评级,Evotec SE(EVO)的总体评级为signal_hold,目标价格为2.80。
Evotec SE(EVO)股票的每股收益(EPS TTM)是多少
Evotec SE(EVO)股票的每股收益(EPS TTM)是-0.33。